Drug Profile
Emavusertib - Aurigene Oncology/Curis
Alternative Names: AU 4948; CA 4948Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Curis; University of Leipzig
- Class Amides; Amines; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Oxazoles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Clk dual-specificity kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Phase I Gastric cancer; Oesophageal cancer
- Preclinical Adenocarcinoma; Malignant melanoma; Rheumatoid arthritis
Most Recent Events
- 24 Mar 2024 Curis temporarily halts the Phase-II clinical trials in Anaemia in Germany (PO) (EudraCT 2020-003986-20)
- 31 Dec 2023 Curis files foreign patent applications for emavusertib and related IRAK-4 inhibitory compounds
- 31 Dec 2023 Curis in-licenses IP rights from Aurigene for emavusertib and related IRAK-4 inhibitory compounds in the US before December 2023